

Novavax to Participate in BofA Securities 2022 Virtual Biotech SMID Cap Conference

December 2, 2022

GAITHERSBURG, Md., Dec. 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Conference Details:

Fireside Chat

Date: Wednesday, December 7, 2022
Time: 9:10 – 9:35 a.m. Eastern Standard Time (EST)
Moderator: Alec Stranahan
Novavax participants: Filip Dubovsky, M.D., Executive Vice President, Chief Medical Officer and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer

Conference

Event: Investor Meetings
Date: Wednesday, December 7, 2022

Recordings

A replay of the recorded fireside session will be available through the Events & presentations page of the Company's website at ir.novavax.com for 90 days from the date of the conference.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. The Novavax COVID-19 vaccine has received authorization from multiple regulatory authorities globally, including the U.S. Food and Drug Administration, the European Commission, and the World Health Organization. The vaccine is currently under review by multiple regulatory agencies worldwide, including for additional indications and populations such as adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating its COVID-19-Influenza Combination (CIC) vaccine candidate in a Phase 1/2 clinical trial, its quadrivalent influenza investigational vaccine candidate, and an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent format Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on [LinkedIn](#).

Contacts:

Investors

Erika Schultz | 240-268-2022
ir@novavax.com

Media

Ali Chartan or Giovanna Chandler | 202-709-5563
media@novavax.com

SOURCE Novavax, Inc.

Image not found or type unknown